Immunic, Inc. (IMUX) shareholders
Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vivo Opportunity, LLC Joint filing with Vivo Opportunity Fund Holdings, L.P. (9.99%), Vivo Opportunity Cayman Fund, L.P. (9.99%) and 1 more | 29,126,906 | 9.99% | 13G (passive) | Feb 17, 2026 |
| Avidity Private Master Fund I LP Joint filing with Avidity Partners Management LP (9.90%), Avidity Partners Management (GP) LLC (9.90%) and 3 more | 13,958,410 | 9.90% | 13G (passive) | Feb 17, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 13,630,601 | 9.99% | 13D (active) | Feb 12, 2026 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 13,350,121 | 9.90% | 13G (passive) | Feb 17, 2026 |
| Janus Henderson Group PLC | 12,016,444 | 9.99% | 13G (passive) | Nov 28, 2025 |
| Deep Track Capital, LP Joint filing with David Kroin (8.69%), Deep Track Biotechnology Master Fund, Ltd. (6.79%) | 11,454,000 | 8.69% | 13G (passive) | Feb 17, 2026 |
| Trails Edge Capital Partners, LP Joint filing with Trails Edge Biotechnology Master Fund, LP (8.70%), Ortav Yehudai (8.70%) | 11,454,000 | 8.70% | 13G (passive) | Feb 17, 2026 |
| Alyeska Investment Group, L.P. Joint filing with Alyeska Fund GP, LLC (9.35%), Anand Parekh (9.35%) | 11,250,000 | 9.35% | 13G (passive) amendment | Sep 30, 2025 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (9.99%), Phillip Gross (9.99%) | 10,479,337 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (8.22%), Daniel Mack (8.22%) | 10,378,406 | 8.22% | 13G (passive) amendment | Dec 31, 2025 |
| abrdn Inc Joint filing with Aberdeen Group plc (8.60%) | 8,243,941 | 8.60% | 13G (passive) | Jun 30, 2025 |
| abrdn Inc. Joint filing with Aberdeen Group plc (6.85%) | 8,243,941 | 6.85% | 13G (passive) amendment | Dec 31, 2025 |
| 683 Capital Management, LLC Joint filing with 683 Capital Partners, LP (5.90%), Zweiman Ari (5.90%) | 7,500,000 | 5.90% | 13G (passive) amendment | Dec 31, 2025 |
| Anand Parekh Joint filing with Alyeska Investment Group, L.P. (6.24%), Alyeska Fund GP, LLC (6.24%) | 7,500,000 | 6.24% | 13G (passive) amendment | Dec 31, 2025 |
| Soleus Capital Master Fund, L.P. Joint filing with Soleus Capital, LLC (5.50%), Soleus Capital Group, LLC (5.50%) and 3 more | 6,792,000 | 5.50% | 13G (passive) | Feb 17, 2026 |
| Avidity Partners Management (Gp) LLC Joint filing with Avidity Partners Management LP (6.60%), Avidity Capital Partners Fund (Gp) LP (6.60%) and 3 more | 6,041,059 | 6.60% | 13G (passive) amendment | Mar 31, 2025 |
| Avidity Partners Management LP Joint filing with Avidity Partners Management (GP) LLC (5.90%), Avidity Capital Partners Fund (GP) LP (5.90%) and 2 more | 5,615,811 | 5.90% | 13G (passive) amendment | Jun 30, 2025 |
| Michael Kramarz Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 1,511,821 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Aberdeen Group plc Joint filing with abrdn Inc. (7.99%) | 1,090,427 | 7.99% | 13G (passive) amendment | Sep 30, 2026 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (7.47%), Daniel Mack (7.47%) | 1,079,843 | 7.47% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMUX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| abrdn plc | 824,393 | 6.04% | $12.67M | −1 | 0.02% |
| Bvf Inc/Il | 765,295 | 5.61% | $11.76M | −2 | 0.30% |
| Millennium Management LLC | 740,347 | 5.43% | $11.38M | +362,355 | 0.00% |
| Avidity Partners Management LP | 669,941 | 4.91% | $10.30M | −66,994 | 1.65% |
| Braidwell LP | 645,010 | 4.73% | $9.91M | New | 0.37% |
| Laurion Capital Management LP | 610,326 | 4.47% | $9.38M | +222,110 | 0.24% |
| Vanguard Capital Management LLC | 571,561 | 4.19% | $8.78M | +57,729 | 0.00% |
| Jones Hill Capital LP | 539,814 | 3.96% | $8.30M | New | 1.76% |
| Nantahala Capital Management, LLC | 501,292 | 3.67% | $7.70M | +250,643 | 0.13% |
| Woodline Partners LP | 471,528 | 3.46% | $7.25M | +374,813 | 0.02% |
| Soleus Capital Management, L.P. | 450,000 | 3.30% | $6.92M | – | 0.24% |
| Propel Bio Management, LLC | 325,022 | 2.38% | $5.00M | +90,544 | 2.61% |
| UBS Group AG | 175,756 | 1.29% | $2.70M | +123,476 | 0.00% |
| Geode Capital Management, LLC | 170,675 | 1.25% | $2.62M | +18,098 | 0.00% |
| 683 Capital Management, LLC | 147,245 | 1.08% | $2.26M | −97,755 | 0.11% |
| Adage Capital Partners Gp, L.L.C. | 139,860 | 1.03% | $2.15M | – | 0.00% |
| BlackRock, Inc. | 132,791 | 0.97% | $2.04M | +36,368 | 0.00% |
| Marshall Wace, Llp | 104,816 | 0.77% | $1.61M | +9,519 | 0.00% |
| Susquehanna International Group, Llp | 90,890 | 0.67% | $1.40M | −11,935 | 0.00% |
| Jane Street Group, LLC | 89,687 | 0.66% | $1.38M | +23,772 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 55 | 9M | 63.7% | 11 / 24 | 15 / 33 | 3M | 1M |
| Q1 2026 | 78 | 7M | 48.1% | 33 / 20 | 7 / 14 | 3M | 1M |
| Q4 2025 | 60 | 5M | 37.6% | 9 / 16 | 9 / 9 | 1M | 0M |
| Q3 2025 | 61 | 4M | 31.3% | 14 / 10 | 10 / 9 | 0M | 1M |
| Q2 2025 | 56 | 5M | 36.8% | 5 / 15 | 14 / 14 | 1M | 1M |
| Q1 2025 | 65 | 4M | 29.7% | 12 / 11 | 18 / 14 | 0M | 2M |
| Q4 2024 | 67 | 5M | 39.0% | 12 / 20 | 16 / 6 | 1M | 1M |
| Q3 2024 | 62 | 6M | 41.0% | 12 / 17 | 14 / 5 | 1M | 0M |
| Q2 2024 | 57 | 6M | 40.9% | 4 / 15 | 17 / 8 | 0M | 0M |
| Q1 2024 | 61 | 6M | 42.1% | 21 / 19 | 7 / 10 | 4M | 0M |
| Q4 2023 | 50 | 2M | 11.1% | 7 / 13 | 14 / 10 | 0M | 0M |
| Q3 2023 | 54 | 2M | 13.5% | 4 / 14 | 19 / 14 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
19 funds held IMUX in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMUX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 399,088 | 2.92% | $6.13M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 159,248 | 1.17% | $2.45M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 63,010 | 0.46% | $942.63K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 46,243 | 0.34% | $710.75K | 0.05% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 30,725 | 0.23% | $472.24K | 0.61% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 29,253 | 0.21% | $437.62K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 17,808 | 0.13% | $266.41K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 9,839 | 0.07% | $147.19K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 8,500 | 0.06% | $118.75K | 0.00% | Jul 31, 2026 |
| Fidelity ZERO Total Market Index Fund | 8,037 | 0.06% | $112.28K | 0.00% | Jul 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 6,993 | 0.05% | $107.48K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 6,232 | 0.05% | $95.79K | 0.00% | Jun 30, 2026 |
| Fidelity ZERO Extended Market Index Fund | 5,154 | 0.04% | $72.00K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 3,121 | 0.02% | $47.97K | 0.02% | Jun 30, 2026 |
| Fidelity Flex Small Cap Index Fund | 2,207 | 0.02% | $30.83K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Duane Nash | Executive Chairman, Director | 45,256 | 0.33% | Jul 18, 2025 |
| Jason Tardio | President and COO | 12,512 | 0.09% | Jun 29, 2026 |
| Glenn Whaley | Chief Financial Officer | 95,510 | 0.70% | Jun 29, 2026 |
| Erik Lundgren | Chief Executive Officer | – | – | Jun 1, 2026 |
| Michael A. Panzara | Chief Medical Officer | – | – | Apr 29, 2026 |
| Andreas Muehler | Chief Medical Officer | 582,466 | 4.27% | Jul 18, 2025 |
| Value Trading Fund OS LP Biotechnology | Director | 427,629 | 3.13% | Sep 18, 2026 |
| Partners L. P/Il Bvf | Director | – | – | Sep 18, 2026 |
| Value Fund L. P. Biotechnology | Director | – | – | Sep 18, 2026 |
| Partners OS Ltd. BVF | Director | – | – | Sep 18, 2026 |
| Ii Gp Llc Bvf | Director | – | – | Sep 18, 2026 |
| Robert Thorvald Nagel | Director | – | – | Sep 18, 2026 |
| Value Fund Ii Lp Biotechnology | Director | – | – | Sep 18, 2026 |
| I. Gp Llc Bvf | Director | – | – | Sep 18, 2026 |
| Inc/Il Bvf | Director | – | – | Sep 18, 2026 |
| Mark N. Lampert | Director | – | – | Sep 18, 2026 |
| Gp Holdings Llc Bvf | Director | 42,762 | 0.31% | Sep 18, 2026 |
| Elena Ridloff | Director | – | – | Aug 10, 2026 |
| Jon Congleton | Director | – | – | Jul 7, 2026 |
| Richard Alan Rudick | Director | 230,375 | 1.69% | Jul 7, 2026 |
| Barclay A. Phillips | Director | – | – | Jul 7, 2026 |
| Joerg Neermann | Director | 200,000 | 1.47% | Jul 7, 2026 |
| Simona Skerjanec | Director | – | – | Jul 7, 2026 |
| Michael W. Bonney | Director | – | – | Jun 29, 2026 |
| Daniel Vitt | Director | 391,877 | 2.87% | Jun 29, 2026 |
| Tamar D. Howson | Director | – | – | Jun 29, 2026 |
| Monika Maria Toernsen | Director | – | – | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Duane Nash Executive Chairman, Director | Jun 13, 2025 | Buy | +20,000 | $0.83 | $16.60K | 36,032 |
| Jason Tardio President and COO | Jun 5, 2025 | Buy | +12,512 | $0.79 | $9.88K | 12,512 |
| Jason Tardio President and COO | Jun 5, 2025 | Buy | +12,512 | $0.79 | $9.88K | 12,512 |
| Joerg Neermann Director | Jun 5, 2025 | Buy | +30,000 | $0.76 | $22.80K | 200,000 |
| Daniel Vitt CEO and Director | Jun 4, 2025 | Buy | +15,000 | $0.77 | $11.55K | 29,000 |
| Daniel Vitt CEO and Director | Jun 4, 2025 | Buy | +15,000 | $0.77 | $11.55K | 29,000 |
| Joerg Neermann Director | Jun 4, 2025 | Buy | +70,000 | $0.77 | $53.90K | 170,000 |
| Glenn Whaley Chief Financial Officer | Jun 3, 2025 | Buy | +45,000 | $0.71 | $31.95K | 95,510 |
| Richard Alan Rudick Director | Jun 3, 2025 | Buy | +143,075 | $0.70 | $100.15K | 230,375 |
| Glenn Whaley Chief Financial Officer | May 30, 2025 | Award | +25,000 | $0.56 | $14.00K | 50,510 |
| Richard Alan Rudick Director | Nov 12, 2024 | Buy | +87,300 | $1.15 | $100.39K | 87,300 |
| Daniel Vitt President and CEO, Director | Feb 26, 2024 | Buy | +14,000 | $1.31 | $18.34K | 390,877 |
| Glenn Whaley Chief Financial Officer | May 15, 2023 | Buy | +5,000 | $1.75 | $8.75K | 25,510 |
| Joerg Neermann Director | Dec 14, 2022 | Buy | +47,000 | $1.26 | $59.22K | 100,000 |
| Joerg Neermann Director | Dec 13, 2022 | Buy | +35,000 | $1.25 | $43.75K | 53,000 |
| Joerg Neermann Director | Nov 23, 2022 | Buy | +18,000 | $1.39 | $25.02K | 18,000 |
| Daniel Vitt President and CEO, Director | Nov 22, 2022 | Buy | +8,000 | $1.35 | $10.80K | 376,877 |
| Glenn Whaley Chief Financial Officer | Nov 7, 2022 | Buy | +5,000 | $1.50 | $7.50K | 20,510 |
| Daniel Vitt President and CEO, Director | Jun 3, 2022 | Buy | +5,000 | $3.10 | $15.50K | 368,877 |
| Glenn Whaley Chief Financial Officer | Jun 3, 2022 | Buy | +3,500 | $3.05 | $10.68K | 12,568 |
| Andreas Muehler Chief Medical Officer | May 12, 2022 | Buy | +3,500 | $5.10 | $17.85K | 297,986 |
| Glenn Whaley Chief Financial Officer | May 12, 2022 | Buy | +3,000 | $5.08 | $15.24K | 9,068 |
| Duane Nash Executive Chairman, Director | May 12, 2022 | Buy | +10,000 | $5.03 | $50.30K | 22,032 |
| Duane Nash Executive Chairman, Director | May 12, 2022 | Gift | −6,000 | – | – | 16,032 |
| Duane Nash Executive Chairman, Director | Nov 8, 2021 | Gift | −3,000 | – | – | 12,032 |
| Daniel Vitt President and CEO, Director | Aug 10, 2021 | Buy | +1,000 | $9.60 | $9.60K | 363,877 |
| Duane Nash Executive Chairman, Director | Aug 10, 2021 | Buy | +1,000 | $9.80 | $9.80K | 15,032 |
| Glenn Whaley PFO and PAO | Aug 10, 2021 | Buy | +1,500 | $9.85 | $14.78K | 3,500 |
| Duane Nash Executive Chairman, Director | May 12, 2021 | Buy | +4,000 | $12.75 | $51.00K | 14,032 |
| Andreas Muehler Chief Medical Officer | Mar 2, 2021 | Buy | +10,006 | $15.54 | $155.49K | 294,486 |
| Glenn Whaley PFO and PAO | Mar 2, 2021 | Buy | +1,000 | $16.48 | $16.48K | 2,000 |
| Glenn Whaley PFO and PAO | Aug 10, 2020 | Buy | +1,000 | $18.96 | $18.96K | 1,000 |
| Manfred Groeppel Chief Operating Officer | Jul 21, 2020 | Sale(10b5-1 plan) | −650 | $15.62 | $10.15K | 278,830 |
| Daniel Vitt Chief Executive Officer, Director | Jul 21, 2020 | Sale(10b5-1 plan) | −1,300 | $15.62 | $20.31K | 362,877 |
| Manfred Groeppel Chief Operating Officer | Jul 20, 2020 | Sale(10b5-1 plan) | −5,000 | $14.44 | $72.20K | 279,480 |
| Daniel Vitt Chief Executive Officer, Director | Jul 20, 2020 | Sale(10b5-1 plan) | −5,000 | $14.44 | $72.20K | 364,177 |
| Duane Nash Director | Dec 4, 2019 | Sale(10b5-1 plan) | −4,400 | $6.96 | $30.62K | 10,032 |
| Duane Nash Director | Dec 3, 2019 | Tax withholding | −7,930 | $7.15 | $56.70K | 14,432 |
| Duane Nash Director | Dec 2, 2019 | Option exercise | +22,157 | – | – | 22,362 |
| Errol R. Halperin Director | Sep 25, 2018 | Sale | −89,417 | $0.29 | $25.93K | 0 |
| Errol R. Halperin Director | Sep 25, 2018 | Sale | −10,000 | $0.29 | $2.90K | 0 |
| Jean Jacques Bienaime Director | Sep 24, 2018 | Sale | −26,619 | $0.30 | $7.99K | 18,500 |
| Douglas Evan Godshall Director | Sep 19, 2018 | Sale | −69,375 | $0.35 | $24.28K | 0 |
| Muneer A. Satter Director, 10% owner | Sep 17, 2018 | Sale | −7,044,777 | $0.29 | $2.04M | 0 |
| Muneer A. Satter Director, 10% owner | Sep 14, 2018 | Sale | −447,500 | $0.36 | $161.10K | 7,044,777 |
| Faheem Hasnain Director | Sep 13, 2018 | Sale | −59,200 | $0.44 | $26.05K | 122,743 |
| Faheem Hasnain Director | Sep 13, 2018 | Sale | −118,243 | $0.44 | $52.03K | 4,500 |
| Jean Jacques Bienaime Director | Sep 13, 2018 | Sale | −20,000 | $0.47 | $9.40K | 45,119 |
| Muneer A. Satter Director, 10% owner | Sep 13, 2018 | Sale | −3,890,000 | $0.50 | $1.95M | 7,492,277 |
| Cheryl Cohen Director | Sep 12, 2018 | Sale | −3,500 | $0.55 | $1.93K | 0 |
| Muneer A. Satter Director, 10% owner | Dec 13, 2017 | Buy | +50,000 | $5.57 | $278.50K | 11,382,277 |
| Muneer A. Satter Director, 10% owner | Dec 12, 2017 | Buy | +50,000 | $5.40 | $270.00K | 11,332,277 |
| Muneer A. Satter Director, 10% owner | Dec 11, 2017 | Buy | +50,000 | $4.96 | $248.00K | 11,282,277 |
| Muneer A. Satter Director, 10% owner | Dec 8, 2017 | Buy | +50,000 | $4.92 | $246.00K | 11,232,277 |
| Muneer A. Satter Director, 10% owner | Dec 7, 2017 | Buy | +50,000 | $4.77 | $238.50K | 11,182,277 |
| Faheem Hasnain Director | Sep 14, 2017 | Buy | +59,200 | $4.19 | $248.05K | 181,943 |
| Muneer A. Satter Director, 10% owner | Sep 14, 2017 | Buy | +30,000 | $4.25 | $127.50K | 11,132,277 |
| Muneer A. Satter Director, 10% owner | Sep 13, 2017 | Buy | +50,000 | $4.13 | $206.50K | 11,102,277 |
| Jean Jacques Bienaime Director | Sep 13, 2017 | Buy | +10,000 | $4.00 | $40.00K | 65,119 |
| Muneer A. Satter Director, 10% owner | Sep 12, 2017 | Buy | +50,000 | $3.74 | $187.00K | 11,052,277 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immunic's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,554 shares on Aug 31, 2026 over the last 90 days.
See a number that looks wrong?